Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 11/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | FECH | P22830 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.42 |
| ▸ | FLT4 | P35916 | 2/20 | 0.41 |
| ▸ | FLT3 | P36888 | 2/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.41 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | FER | P16591 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | CLK2 | P49760 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2037624 | 1.00 | KDM4E (0.47) | KDM4ECHEK1HRH3FECHKCNH2 | |
| SCHEMBL13677587 | 1.00 | KDM4E (0.47) | KDM4ECHEK1HRH3FECHKCNH2 | |
| SCHEMBL2036333 | 0.94 | KDM4E (0.51) | KDM4ECHEK1FECHKCNH2CDK5 | |
| SCHEMBL2031893 | 0.91 | CHEK1 (0.49) | CHEK1HRH3FECHKCNH2CDK5 | |
| SCHEMBL5063309 | 0.90 | HCRTR1 (0.48) | KDM4ECHEK1HRH3 | |
| SCHEMBL2034851 | 0.90 | CHEK1 (0.51) | KDM4ECHEK1FECHKCNH2CDK5 | |
| SCHEMBL5164420 | 0.89 | CHEK1 (0.44) | CHEK1HRH3FECHKCNH2CDK5 | |
| SCHEMBL5164315 | 0.89 | IDH2 (0.46) | KDM4ECHEK1HRH3FECHKCNH2 | |
| SCHEMBL27644594 | 0.89 | CHEK1 (0.44) | CHEK1HRH3FECHKCNH2CDK5 | |
| SCHEMBL2036172 | 0.87 | KDM4E (0.41) | KDM4EHRH3CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100374425-C | Aryl and heteroaryl urea CHK1 inhibitors for use as radiosensitizers and chamosensitizers | YILE LILY CO LTD (US) | 2008-03-12 | — | — | CN | claimed |
| CN-1507436-A | Aryl and heteroaryl urea CHK1 inhibitors for use as radiosensitizers and chamosensitizers | — | 2004-06-23 | — | — | CN | claimed |
| CN-112472699-A | Combination methods for improving the therapeutic benefit of bisantrene and derivatives | 种族肿瘤学公司 | 2021-03-12 | — | — | CN | disclosed |
| EP-1379510-B1 | ARYL AND HETEROARYL UREA CHK1 INHIBITORS FOR USE AS RADIOSENSITIZERS AND CHEMOSENSITIZERS | ICOS CORP (US) | 2011-06-01 | — | — | EP | disclosed |
| US-20100105683-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | KEEGAN KATHLEEN S | 2010-04-29 | — | — | US | disclosed |
| US-20100105683-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | KEEGAN KATHLEEN S | 2010-04-29 | — | — | US | disclosed |
| US-7608618-B2 | Urea or thiourea substituted 1,4-pyrazine compounds useful as anti-cancer agents and for inhibiting Chk1 | ICOS CORPORATION (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608618-B2 | Urea or thiourea substituted 1,4-pyrazine compounds useful as anti-cancer agents and for inhibiting Chk1 | ICOS CORPORATION (US) | 2009-10-27 | — | — | US | disclosed |
| CN-100374425-C | Aryl and heteroaryl urea CHK1 inhibitors for use as radiosensitizers and chamosensitizers | YILE LILY CO LTD (US) | 2008-03-12 | — | — | CN | disclosed |
| CN-1507436-A | Aryl and heteroaryl urea CHK1 inhibitors for use as radiosensitizers and chamosensitizers | — | 2004-06-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105683-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | CHEK1, PCNA, CHEK2 | KDM4E 2395/4885CHEK1 1/4885HRH3 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.